Swiss biotech firm halts trial of heart drug

11/8/2004 | Bloomberg

Actelion plans to tell investors today that it stopped the phase III clinical trial of Veletri, a proposed treatment for acute heart failure, because the study failed to show effectiveness. The study's steering committee recommended stopping the trial because 1,300 patients showed no statistically significant results. No safety issues surfaced in the trial, the firm said.

View Full Article in:

Bloomberg

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Cargill
Wayzata, MN
Director of Clinical Research
Regenesis Biomedical, Inc.
Scottsdale, AZ
Actuary
Meridian Health Plan
Detroit, MI
Assistant Vice President - Dental Director
MetLife
Bridgewater, NJ